23-Apr-14 World Orphan Drug Congress
With a network of skilled staff operating in more than 30 countries, Premier Research is able to manage large global trials and programs.
Executive Director, Oncology
Mr. Drouet plays a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology business.
Michael H. Skinner
Executive Director, Global Medical Affairs and Strategic Consulting
Michael H. Skinner, MD, PharmD, provides consulting, strategic development and medical monitoring services for clinical programs involving analgesia, neurology, psychiatry, medical devices, and other medical products.
Executive Director, Pediatrics and Rare Diseases
Angi Robinson, BS, has been conducting global trials in pediatrics and rare diseases for more than ten years at Premier Research.
Vice President, Analgesia
Mr. Michael Kuss is Premier Research’s therapeutic leader in analgesia and rheumatology. He is also responsible for strategic, commercial, organizational and financial aspects of our Clinical Research Centers, which specialize in Phase I trials.
Charli G. Sanders
Vice President, Global Regulatory Affairs, Compliance and Pediatric Strategic Consulting
Dr. Sanders, MD, has provided senior level FDA and global regulatory and clinical development input, expertise and oversight for research progression, compilation, submission of INDs, pre-NDA documents, clinical research protocols and NDAs for products in various therapeutic areas.
Executive Director, Clinical Research Centers
Stephen Daniels, DO, is the Executive Director of the Clinical Research Centers, a position he has held for over 14 years.
Clinical Research Expertise from Around the Globe
Our extensive network enables us to apply local knowledge and expertise to international projects. Our broad operational footprint allows many options for subject enrollment and enables access to diverse patient populations. Learn More
From 2008 through 2013 Premier Research conducted 60% of their clinical trials in North America and 40% throughout Europe.